- Home
- LDWY vs GTBP Comparison
LDWY vs GTBP Comparison
Compare LDWY & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- GTBP
- Stock Information
- Founded
- LDWY 1990
- GTBP 1965
- Country
- LDWY United States
- GTBP United States
- Employees
- LDWY N/A
- GTBP N/A
- Industry
- LDWY Advertising
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- GTBP Health Care
- Exchange
- LDWY Nasdaq
- GTBP Nasdaq
- Market Cap
- LDWY 9.2M
- GTBP 5.5M
- IPO Year
- LDWY 1991
- GTBP N/A
- Fundamental
- Price
- LDWY $5.15
- GTBP $0.83
- Analyst Decision
- LDWY
- GTBP Strong Buy
- Analyst Count
- LDWY 0
- GTBP 1
- Target Price
- LDWY N/A
- GTBP $11.00
- AVG Volume (30 Days)
- LDWY 5.7K
- GTBP 441.9K
- Earning Date
- LDWY 08-28-2025
- GTBP 11-13-2025
- Dividend Yield
- LDWY N/A
- GTBP N/A
- EPS Growth
- LDWY N/A
- GTBP N/A
- EPS
- LDWY 1.66
- GTBP N/A
- Revenue
- LDWY $71,244,000.00
- GTBP N/A
- Revenue This Year
- LDWY N/A
- GTBP N/A
- Revenue Next Year
- LDWY N/A
- GTBP N/A
- P/E Ratio
- LDWY $3.18
- GTBP N/A
- Revenue Growth
- LDWY 187.12
- GTBP N/A
- 52 Week Low
- LDWY $3.02
- GTBP $0.63
- 52 Week High
- LDWY $6.19
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- LDWY 50.99
- GTBP 30.89
- Support Level
- LDWY N/A
- GTBP $0.63
- Resistance Level
- LDWY $5.35
- GTBP $0.95
- Average True Range (ATR)
- LDWY 0.29
- GTBP 0.11
- MACD
- LDWY -0.25
- GTBP 0.03
- Stochastic Oscillator
- LDWY 83.20
- GTBP 35.45
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.